Last checked September 2026 against 30 sources · Editorial policy
Non-hormonal treatments for hot flashes
Effective non-hormonal treatments for hot flashes include fezolinetant (Veozah) and elinzanetant (Lynkuet), low-dose paroxetine and other SSRIs or SNRIs, gabapentin and oxybutynin, which cut hot flashes by roughly 40% to 65%. CBT, clinical hypnosis and weight loss if you're overweight also help. For vaginal dryness, use moisturizers and lubricants or ask about ospemifene. Supplements and herbal remedies aren't recommended.
Fezolinetant, SSRIs, SNRIs, gabapentin, oxybutynin and CBT all reduce hot flashes without hormones. How well each works and who they suit.
Non-hormonal menopause treatment: expectation vs reality
What people often expect
“Without hormones, the only options are supplements and putting up with symptoms”
What the evidence shows
The North American Menopause Society's 2023 review found good evidence for several non-hormonal treatments: CBT, clinical hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant, with oxybutynin, weight loss and stellate ganglion block also recommended. It didn't recommend supplements, herbal remedies, soy, paced breathing, yoga, cooling techniques or acupuncture for hot flashes.
Non-hormonal treatments for menopause symptoms explained
Who needs non-hormonal menopause treatment
Hormone therapy is the most effective treatment for hot flashes, but some women can't or don't want to take it. The North American Menopause Society points to women with estrogen-dependent cancers or cardiovascular disease, and to personal preference. The NHS lists a history of breast, ovarian or uterine cancer, blood clots, liver disease and untreated high blood pressure as reasons HRT may not suit.
Learn more →Neurokinin blockers: fezolinetant and elinzanetant
These are the first non-hormonal medicines designed specifically for hot flashes. Fezolinetant (Veozah, 45 mg daily) blocks the neurokinin 3 receptor; elinzanetant (Lynkuet, 120 mg at bedtime) blocks neurokinin 1 and 3 receptors. Both reduced hot flashes more than placebo from week 4. Both need liver blood tests, and Veozah carries a boxed warning for rare serious liver injury.
Learn more →Non-hormonal hot flash medication: SSRIs and SNRIs
Low-dose paroxetine (7.5 mg, Brisdelle) is FDA-approved for hot flashes, and escitalopram, citalopram, venlafaxine and desvenlafaxine are used off-label. They reduce hot flash frequency by about 40% to 65%. In a trial, more than half of women on escitalopram had at least a 50% drop in hot flashes, compared with 36% on placebo. Paroxetine can reduce tamoxifen's effect.
Learn more →Gabapentin and oxybutynin
Gabapentin at 900 mg a day cut hot flash severity by 46% in a trial of women with breast cancer, and 600 mg performed about as well as a low-dose estradiol patch in another. Oxybutynin, a bladder medicine, reduced hot flashes by 9.48 a day vs 4.69 on placebo, with dry mouth in about half of users. Both are inexpensive generics.
Learn more →CBT, hypnosis and weight loss
Cognitive behavioral therapy and clinical hypnosis are recommended with the strongest level of evidence by The North American Menopause Society. NICE advises considering menopause-specific CBT for hot flashes, sleep problems and low mood. For women who are overweight, weight loss is also recommended. These approaches have no drug side effects and can be combined with medicines.
Learn more →Non-hormonal treatment for vaginal dryness
Vaginal moisturizers used regularly and lubricants during sex help dryness without hormones, and a 2024 review found moisturizers may improve dryness. Ospemifene (Osphena) is a non-estrogen daily pill that improved dryness and painful sex in trials. Prasterone inserts are another option, though they contain DHEA, a hormone precursor. Low-dose vaginal estrogen remains the most effective choice.
Learn more →Non-hormonal help for mood and sleep
If low mood, depression or anxiety come with menopause, the NHS says antidepressants may be offered, and SSRIs and SNRIs can also ease hot flashes. For insomnia, CBT for insomnia improved sleep in a trial of women around menopause, with benefits still present at 24 weeks. Paroxetine 7.5 mg cut night-time awakenings from hot flashes by 39% vs 28% on placebo within 4 weeks and added about 31 minutes of sleep.
Learn more →Non-hormonal menopause supplements
Supplements marketed as hormone-free menopause relief don't have good evidence. In a JAMA meta-analysis, red clover didn't reduce hot flashes and soy extracts gave mixed results. The North American Menopause Society doesn't recommend supplements, herbal remedies or soy for hot flashes, and the NHS says herbal remedies have very little evidence on effectiveness or safety.
Learn more →What non-hormonal treatments don't do
Non-hormonal hot flash medicines don't protect bone the way estrogen does, and they don't treat vaginal dryness. If you've had early menopause, bone health needs separate attention. For osteoporosis prevention, FDA labels advise considering non-estrogen medicines first when bone is the only concern, so talk to your doctor about bone density testing and treatment.
Learn more →Non-hormonal options after breast cancer
Women who've had breast cancer often can't take estrogen, so non-hormonal options matter most for them. Venlafaxine and gabapentin were tested in breast cancer survivors: venlafaxine 75 mg cut hot flash scores by 61% after 4 weeks, and gabapentin 900 mg cut severity by 46% at 8 weeks. Paroxetine is usually avoided with tamoxifen. For vaginal dryness, non-hormonal moisturizers come first.
Learn more →How long non-hormonal treatments take to work
Most non-hormonal hot flash medicines show an effect within 4 weeks, the first checkpoint used in trials of paroxetine, fezolinetant and elinzanetant, and are judged fully at around 12 weeks. Gabapentin's effect was clear by 4 weeks too. CBT takes several weekly sessions. If one option doesn't help after about 3 months, switching to another class often does.
Learn more →Non-hormonal treatments by the numbers
From the studies on this page
reduction in hot flash frequency with SSRIs, SNRIs and gabapentin
40% to 65%
reduction in hot flash severity with gabapentin 900 mg in a trial
46%
of women on oxybutynin rated their hot flashes much better at 12 weeks
73%
4.60 vs 3.20
Most non-hormonal medicines are less effective than estrogen, which reduces hot flashes by about 75%.
Non-hormonal hot flash treatments that work
Fezolinetant or elinzanetant
Strong evidenceTargeted non-hormonal pills for moderate to severe hot flashes, working from week 4. Liver tests are needed, and Veozah has a boxed warning for rare liver injury. Elinzanetant can cause sleepiness, so it's taken at bedtime.
Related guide →SSRIs and SNRIs
Strong evidenceParoxetine 7.5 mg is FDA-approved for hot flashes; venlafaxine, escitalopram and desvenlafaxine are alternatives. They can help mood too. Avoid paroxetine with tamoxifen.
Related guide →Gabapentin
Strong evidenceEffective at 900 mg a day and inexpensive. Drowsiness and dizziness are common side effects. In one trial, 600 mg worked about as well as a low-dose estradiol patch.
Related guide →Oxybutynin
Strong evidenceHalved hot flashes in a 12-week trial and improved sleep quality, but dry mouth is common. It's an inexpensive generic.
CBT and clinical hypnosis
Strong evidenceRecommended with strong evidence; help hot flashes, sleep and mood without medicines. NICE recommends considering CBT for hot flashes alongside or instead of HRT.
Supplements and herbal remedies
No good evidenceNot recommended for hot flashes; red clover didn't work and soy results are mixed. The NHS says herbal remedies have very little evidence on how well they work or how safe they are.
Related guide →
When to see a doctor about non-hormonal treatment
Hot flashes disrupting your life and HRT isn't an option
See a doctor about non-hormonal prescription options; several have good evidence.
More →Taking tamoxifen or another breast cancer medicine
Check with your oncology team before starting any hot flash treatment, because of interactions.
Urgent: Signs of liver problems on Veozah or Lynkuet
Stop the medicine and contact your prescriber if you notice unusual tiredness, nausea, itching, yellow skin or eyes, or dark urine.
Urgent: Thoughts of self-harm on an antidepressant
Get help now: call or text 988, or call 911 in an emergency.
Non-hormonal menopause relief: questions women ask
What is the best non-hormonal hot flash medication?
There's no single best one. Fezolinetant and elinzanetant target the cause most directly; paroxetine 7.5 mg is FDA-approved and helps mood; gabapentin suits night-time symptoms; oxybutynin is cheap and effective. The choice depends on your health, medicines and side effects.
Are there non-hormonal treatments for menopause symptoms besides hot flashes?
Yes. Vaginal moisturizers, lubricants and ospemifene help vaginal symptoms; CBT for insomnia helps sleep; antidepressants and talking therapy help low mood. Weight-bearing exercise, calcium and vitamin D support bone.
Can you manage menopause without hormone replacement therapy?
Yes. Many women manage with non-hormonal medicines, CBT and lifestyle changes. They're usually less effective than estrogen for hot flashes and don't protect bone or treat vaginal dryness, so those need separate attention.
Is there a non-hormonal menopause supplement that works?
No supplement has good evidence. Red clover didn't reduce hot flashes and soy results are mixed. The North American Menopause Society doesn't recommend supplements or herbal remedies. Prescription non-hormonal options work much better.
Do non-hormonal hot flash drugs have side effects?
Yes: SSRIs and SNRIs can cause nausea and sleep changes; gabapentin causes drowsiness and dizziness; oxybutynin causes dry mouth; fezolinetant needs liver monitoring; elinzanetant can cause sleepiness.
What is hormone-free menopause relief for vaginal dryness?
Start with a vaginal moisturizer used a few times a week and a lubricant for sex. If that isn't enough, ospemifene is a non-estrogen pill option, and low-dose vaginal estrogen is the most effective treatment if you can use it.
How fast do non-hormonal hot flash treatments work?
Most show an effect within 4 weeks in trials, and their full effect is judged at about 12 weeks. If one doesn't help after about 3 months, ask about switching to a different class of medicine or adding CBT.
Sources
- The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
- Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405-420.
- Prescribing information: Veozah (fezolinetant tablets). Astellas Pharma, 2026. DailyMed, US National Library of Medicine.
- Prescribing information: Lynkuet (elinzanetant capsules). Bayer HealthCare, 2026. DailyMed, US National Library of Medicine.
- The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.
- Prescribing information: Osphena (ospemifene tablets). Duchesnay, 2025. DailyMed, US National Library of Medicine.
- NHS. About hormone replacement therapy (HRT).
- US Food and Drug Administration. Drug safety communication: FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant). December 2024.
- Prescribing information: Brisdelle (paroxetine 7.5 mg capsules). Legacy Pharma, 2025. DailyMed, US National Library of Medicine.
- Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305(3):267-74.
- Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9488):818-24.
- Aguirre W, Chedraui P, Mendoza J, et al. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. Gynecol Endocrinol. 2010;26(5):333-7.
- Simon JA, Gaines T, LaGuardia KD; Extended-Release Oxybutynin Therapy for VMS Study Group. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause. 2016;23(11):1214-1221.
- NICE. Menopause: identification and management (NG23). Updated 2024.
- Danan ER, Sowerby C, Ullman KE, et al. Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review. Ann Intern Med. 2024;177(10):1400-1414.
- Prescribing information: Intrarosa (prasterone vaginal inserts). Millicent, 2026. DailyMed, US National Library of Medicine.
- NHS. Treatment for menopause and perimenopause.
- McCurry SM, Guthrie KA, Morin CM, et al. Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial. JAMA Intern Med. 2016;176(7):913-20.
- Pinkerton JV, Joffe H, Kazempour K, et al. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Menopause. 2015;22(1):50-8.
- Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057-71.
- The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- Prescribing information: Estradiol tablets USP. Teva Pharmaceuticals, 2024. DailyMed, US National Library of Medicine.
- US Preventive Services Task Force. Osteoporosis to prevent fractures: screening. 2025.
- Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059-63.
- Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause. 2018;25(6):596-608.
- Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20(10):1027-35.
- Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024;332(16):1343-54.
- Federal Communications Commission. 988 Suicide & Crisis Lifeline.
- National 911 Program. 911.gov.
- Office on Women's Health, US Department of Health and Human Services. Menopause and your health.
See our editorial policy.
Related guides
Hot flash treatment
HRT is the most effective hot flash treatment. Non-hormonal options include fezolinetant, SSRIs, gabapentin an…
Veozah (fezolinetant) for hot flashes
Veozah is a non-hormonal pill for hot flashes. Side effects and the liver warning, cost and the savings card, …
Paroxetine and SSRIs for hot flashes
Low-dose paroxetine (7.5 mg) is FDA-approved for hot flashes. How it compares with HRT and other SSRIs, side e…
Gabapentin for menopause hot flashes
Gabapentin, often taken at bedtime, reduces hot flashes and night sweats. Typical dosing, how well it works co…